Investors / Japan / Axil Capital
Axil Capital
Venture capital · Tokyo, Japan · Asia Pacific
Axil Capital is a venture capital firm that invests in biomedical and healthcare technology across the life sciences. Established in 2017 as a spinoff from Mizuho Securities, it invests from seed through crossover stage and supports portfolio companies with its global network.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechhealthcaremedical devicesdigital healththerapeutics
Your fit with Axil Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAxil Capital lists 14 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Growth, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 54% of its companies are based in Japan. It invests most often alongside 3B Future Health Fund, 3E Bioventures Capital and Abies Ventures.
Counts come from funding rounds that name Axil Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Axil Capital's whole history. Rounds on record name 1 company; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 0% |
| Growth | 100% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 36th | 14 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 70th | 7% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| 3B Future Health Fund | 1 |
| 3E Bioventures Capital | 1 |
| Abies Ventures | 1 |
| Beta Venture Capital | 1 |
| JAFCO | 1 |
| Keio Innovation Initiative | 1 |
| Kobe University Capital | 1 |
| LG Technology Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers14100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with 3B Future Health Fund
Compare Axil Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Axil Capital| Date | Company | Stage |
|---|---|---|
| 7 Jul 2026 | Series C+ |
Round details for Axil Capital
Amounts, full round histories and every co-investor in Axil Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Ascendo Biotechnology is a clinical-stage biopharmaceutical company pioneering a first-in-class innate immune checkpoint platform. | Healthcare & Biotech | Portfolio page | ||
| C4 Therapeutics develops a new generation of medicine using targeted protein degradation to treat disease | Healthcare & Biotech | Portfolio page | ||
| Cranebio provides simple and low-cost testing systems to deliver health to many people. | Healthcare & Biotech | Portfolio page | ||
| CynosBio develops and sells regenerative medicine products, including cell sheets and collagen matrix products, for various medical applications. | Healthcare & Biotech | Portfolio page | ||
| The company develops and sells digital therapeutic products, including apps for mental health treatment. | Healthcare & Biotech | Portfolio page | ||
| Eurus Therapeutics Inc. develops genetic medicines based on innovative genome integration technologies. | Healthcare & Biotech | Portfolio page | ||
| Fore Biotherapeutics develops targeted therapies for treating cancers. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| Himuka AM Pharma develops and conducts clinical trials for pharmaceutical products such as HM101 and HM201. | Healthcare & Biotech | Portfolio page | ||
| HoneyBear Biosciences, Inc is a Taiwan-based biotech company that is leveraging its proprietary antibody-drug conjugation platform for global drug development. | Healthcare & Biotech | Portfolio page | ||
| The company delivers clinical education using virtual reality, creating a realistic and immersive experience of the clinical situation. | Healthcare & Biotech | Portfolio page | ||
| LinqMed Inc. develops radiopharmaceuticals for cancer treatment. | Healthcare & Biotech | Portfolio page | ||
| Pulmotect, Inc. develops products for severe respiratory diseases | Healthcare & Biotech | Portfolio page | ||
| Rakuten Medical is developing a cancer therapy platform based on photoimmunotherapy | Healthcare & Biotech | Portfolio page | ||
| United Immunity develops next-generation in vivo cell therapies using its Myeloid Targeting Platform technology to selectively target and program immune cells in the body for the treatment of various diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- axilcapital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 7 Jul 2026
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Axil Capital's profile as data
Pull Axil Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/axilcapital.com
# also
GET /v1/firms/axilcapital.com/portfolio
GET /v1/firms/axilcapital.com/coinvestors
GET /v1/firms/axilcapital.com/news